Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 58,988 Shares

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc acquired 58,988 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was purchased at an average cost of $14.47 per share, with a total value of $853,556.36. Following the completion of the transaction, the director now owns 14,881,578 shares in the company, valued at $215,336,433.66. The trade was a 0.40 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The stock was acquired at an average price of $14.78 per share, for a total transaction of $2,333,466.40.
• On Tuesday, December 24th, Ecor1 Capital, Llc acquired 11,958 shares of Zymeworks stock. The shares were acquired at an average price of $14.12 per share, with a total value of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc bought 16,692 shares of Zymeworks stock. The stock was acquired at an average cost of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Stock Up 1.0 %

Shares of NYSE:ZYME opened at $14.78 on Friday. The company has a market cap of $1.02 billion, a PE ratio of -9.85 and a beta of 1.12. Zymeworks Inc. has a fifty-two week low of $7.97 and a fifty-two week high of $17.70. The firm has a 50-day simple moving average of $14.39 and a 200 day simple moving average of $12.18.

Zymeworks (NYSE:ZYME) last issued its earnings results on Thursday, October 31st. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The company had revenue of $16.00 million during the quarter, compared to the consensus estimate of $17.90 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. Zymeworks’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.41) earnings per share. As a group, research analysts forecast that Zymeworks Inc. will post -1.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ZYME shares. Leerink Partnrs raised shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 7th. HC Wainwright reissued a “neutral” rating and set a $12.00 price objective on shares of Zymeworks in a report on Friday, November 22nd. Wells Fargo & Company upped their target price on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. Leerink Partners upgraded Zymeworks from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $10.00 to $25.00 in a research note on Thursday, November 7th. Finally, Citigroup upped their price objective on Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.17.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in shares of Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after acquiring an additional 1,525 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in Zymeworks during the 3rd quarter valued at about $47,000. nVerses Capital LLC acquired a new position in Zymeworks during the 3rd quarter valued at about $79,000. Quest Partners LLC grew its position in Zymeworks by 8,049.6% in the 2nd quarter. Quest Partners LLC now owns 9,209 shares of the company’s stock worth $78,000 after purchasing an additional 9,096 shares during the last quarter. Finally, MQS Management LLC acquired a new stake in shares of Zymeworks in the second quarter valued at approximately $92,000. 92.89% of the stock is currently owned by institutional investors.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.